Percepção dos pacientes sobre uso de medicamentos à base de canabidiol

Abstract

The growing therapeutic application of compounds derived from Cannabis sativa, especially cannabidiol (CBD), has attracted the interest of patients, healthcare professionals, and researchers due to its potential therapeutic effects. However, its medicinal use still faces significant barriers, including social stigma, limited access, and regulatory challenges. In this context, understanding the perceptions of patients who use cannabidiol-based medications is essential to inform clinical practice and guide public policy on this topic. This study aimed to evaluate whether patients experienced improvements in the symptoms of their conditions and in their quality of life after initiating treatment with CBD-based medications. It also sought to assess how patients became aware of this therapeutic option and to explore the associated socioeconomic impacts. This is a cross-sectional, observational study with a quantitative approach, conducted through a structured questionnaire distributed online via Google Forms®. Inclusion criteria comprised individuals over 18 years of age, in continuous use of CBD medications, who voluntarily consented to participate in the study. Data collection took place between October 2024 and February 2025. Twenty-seven individuals participated, with a balanced gender distribution. Most participants had completed higher education (55.6%) and were between 31 and 45 years old. The main clinical conditions treated were chronic pain, sleep disorders, anxiety, and depression. Among the reported outcomes, 33.3% noticed improved sleep, 29.6% reported pain relief, and 25.9% observed reductions in anxiety and depressive symptoms. Additionally, 63% of respondents continued to use conventional therapies such as antidepressants and anticonvulsants. Notably, 37% of participants learned about CBD treatment through media sources, surpassing medical recommendations (22%). Regarding socioeconomic impact, 44% of patients reported a moderate impact on the family budget, while 25% considered the impact significant. Furthermore, 29.6% indicated that they had considered interrupting treatment due to financial constraints or difficulties in accessing the medication. In conclusion, the use of cannabidiol was associated with perceived benefits for most patients, particularly in the management of pain, anxiety, insomnia, and depression, contributing to improvements in quality of life. However, challenges related to access, regulation, and professional training remain. The findings highlight the need for public policies that support the safe and equitable expansion of CBD use, promote clinical research, reduce stigma, and enable integration into the scope of the SUS.